251 related articles for article (PubMed ID: 9695714)
21. Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms.
Coller JK; Somogyi AA; Bochner F
Br J Clin Pharmacol; 1999 Aug; 48(2):158-67. PubMed ID: 10417492
[TBL] [Abstract][Full Text] [Related]
22. Reproducibility over time of mephenytoin and debrisoquine hydroxylation phenotypes.
Llerena A; Valdivielso MJ; Benítez J; Bertilsson L
Pharmacol Toxicol; 1993 Jul; 73(1):46-8. PubMed ID: 8234192
[TBL] [Abstract][Full Text] [Related]
23. Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activity.
Klaassen T; Jetter A; Tomalik-Scharte D; Kasel D; Kirchheiner J; Jaehde U; Fuhr U
Eur J Clin Pharmacol; 2008 Apr; 64(4):387-98. PubMed ID: 18071681
[TBL] [Abstract][Full Text] [Related]
24. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
[TBL] [Abstract][Full Text] [Related]
25. The influence of St John's Wort on CYP2C19 activity with respect to genotype.
Wang LS; Zhu B; Abd El-Aty AM; Zhou G; Li Z; Wu J; Chen GL; Liu J; Tang ZR; An W; Li Q; Wang D; Zhou HH
J Clin Pharmacol; 2004 Jun; 44(6):577-81. PubMed ID: 15145964
[TBL] [Abstract][Full Text] [Related]
26. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors.
Kaisary A; Smith P; Jaczq E; McAllister CB; Wilkinson GR; Ray WA; Branch RA
Cancer Res; 1987 Oct; 47(20):5488-93. PubMed ID: 3652049
[TBL] [Abstract][Full Text] [Related]
27. Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans.
Böttiger Y; Dostert P; Benedetti MS; Bani M; Fiorentini F; Casati M; Poggesti I; Alm C; Alvan G; Bertilsson L
Br J Clin Pharmacol; 1996 Dec; 42(6):707-11. PubMed ID: 8971425
[TBL] [Abstract][Full Text] [Related]
28. No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects.
Laine K; Tybring G; Bertilsson L
Clin Pharmacol Ther; 2000 Aug; 68(2):151-9. PubMed ID: 10976546
[TBL] [Abstract][Full Text] [Related]
29. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4'-hydroxylation phenotype and genotype.
Tanaka M; Ohkubo T; Otani K; Suzuki A; Kaneko S; Sugawara K; Ryokawa Y; Hakusui H; Yamamori S; Ishizaki T
Clin Pharmacol Ther; 1997 Dec; 62(6):619-28. PubMed ID: 9433390
[TBL] [Abstract][Full Text] [Related]
30. Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects.
Chen XP; Tan ZR; Huang SL; Huang Z; Ou-Yang DS; Zhou HH
Clin Pharmacol Ther; 2003 Mar; 73(3):264-71. PubMed ID: 12621391
[TBL] [Abstract][Full Text] [Related]
31. Assessment of cytochrome P450 activity by a five-drug cocktail approach.
Zhu B; Ou-Yang DS; Chen XP; Huang SL; Tan ZR; He N; Zhou HH
Clin Pharmacol Ther; 2001 Nov; 70(5):455-61. PubMed ID: 11719732
[TBL] [Abstract][Full Text] [Related]
32. Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes.
Hall SD; Guengerich FP; Branch RA; Wilkinson GR
J Pharmacol Exp Ther; 1987 Jan; 240(1):216-22. PubMed ID: 2879902
[TBL] [Abstract][Full Text] [Related]
33. [The molecular mechanism of polymorphism of S-mephenytoin hydroxylative metabolism].
Lou YQ; Kuang TY
Sheng Li Ke Xue Jin Zhan; 1995 Jan; 26(1):23-8. PubMed ID: 7604218
[TBL] [Abstract][Full Text] [Related]
34. A methodological investigation on the estimation of the S-mephenytoin hydroxylation phenotype using the urinary S/R ratio.
Tybring G; Bertilsson L
Pharmacogenetics; 1992 Oct; 2(5):241-3. PubMed ID: 1306124
[TBL] [Abstract][Full Text] [Related]
35. Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents.
LLerena A; Herraíz AG; Cobaleda J; Johansson I; Dahl ML
Clin Pharmacol Ther; 1993 Dec; 54(6):606-11. PubMed ID: 7903915
[TBL] [Abstract][Full Text] [Related]
36. Stereoselective disposition of mianserin is related to debrisoquin hydroxylation polymorphism.
Dahl ML; Tybring G; Elwin CE; Alm C; Andreasson K; Gyllenpalm M; Bertilsson L
Clin Pharmacol Ther; 1994 Aug; 56(2):176-83. PubMed ID: 8062494
[TBL] [Abstract][Full Text] [Related]
37. Species differences in stereoselective metabolism of mephenytoin by cytochrome P450 (CYP2C and CYP3A).
Yasumori T; Chen L; Nagata K; Yamazoe Y; Kato R
J Pharmacol Exp Ther; 1993 Jan; 264(1):89-94. PubMed ID: 8423554
[TBL] [Abstract][Full Text] [Related]
38. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study.
Balian JD; Sukhova N; Harris JW; Hewett J; Pickle L; Goldstein JA; Woosley RL; Flockhart DA
Clin Pharmacol Ther; 1995 Jun; 57(6):662-9. PubMed ID: 7781266
[TBL] [Abstract][Full Text] [Related]
39. P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism.
Hadama A; Ieiri I; Morita T; Kimura M; Urae A; Irie S; Kaneda T; Mamiya K; Tashiro N; Higuchi S; Otsubo K
Ther Drug Monit; 2001 Apr; 23(2):115-8. PubMed ID: 11294510
[TBL] [Abstract][Full Text] [Related]
40. CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system.
Ford GA; Wood SM; Daly AK
Br J Clin Pharmacol; 2000 Jul; 50(1):77-80. PubMed ID: 10886124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
